Clinical background:
Quantifying measurable residual disease is crucial for monitoring haematological malignancy such as AML. It can provide prognostic information in addition to directing management. MRD can be performed by flow cytometry or genetics depending on the disease. Molecular MRD is available for AML including monitoring patients with NPM1 mutation, PML::RARA, RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, NUP98 rearrangement or KMT2A rearrangement. Other fusions may also be measurable.
Specimen container paediatric:
EDTA
Specimen container adult:
EDTA
Minimum volume paediatric:
5 mL
Minimum volume adult:
5 mL
Special requirements:
Please complete NEHODS request form
Sample Stability:
Should be analysed within 48 hours
Transport requirements:
Samples should be sent to laboratory immediately.
Freq Analysis:
Analysis is daily but please only perform blood tests and bone marrow biopsies for MRD on Mondays, Tuesdays and Wednesday mornings.
Add On Test:
Depending on assay may be added on to previous samples. Please discuss.
Quality Assurance:
N/A
Interpretation:
By referring site
Reference Ranges:
N/A
Factors Affecting Result:
Quality and size of sample
Referenced Documents:
N/A
Other Info:
Please only perform blood tests and bone marrow biopsies for MRD on Mondays, Tuesdays and Wednesday mornings. All of these tests are significantly affected by delays to analysis and couriers cannot get the sample to the reference laboratory unless it reaches NEHODS in time.